Alnylam Pharmaceuticals Inc (ALNY) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Total Assets Chart for Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc (ALNY) total assets for FY2025 were USD 5.0B, a 17.1% change from FY2024. Alnylam Pharmaceuticals Inc's total assets grew from USD 16.1M in 2002 to USD 5.0B in 2025 (30725.7% over 23 years). Total assets compound annual growth rate: 5-year CAGR of 7.8%, 10-year CAGR of 13.6%, 20-year CAGR of 21.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $31.65B
- Implied Share Price
- $236.56
- Enterprise Value
- $29.94B
- Revenue (TTM)
- $4.80B
- EBITDA
- $1.05B
- Profit Margin
- 16.13%
- Trailing P/E
- 41.65
- Forward P/E
- 27.55
- Price/Book (MRQ)
- 23.62
- Price/Sales (TTM)
- 6.59
- EV/EBITDA
- 27.09
- EV/Revenue
- 6.23
- Dividend Yield
- —
- Book Value
- $10.12
- Free Cash Flow (FY2025)
- $465.38M
- Free Cash Flow Yield
- 1.47%
Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.